scispace - formally typeset
N

Nicolas F M Porta

Researcher at Northwestern University

Publications -  44
Citations -  1407

Nicolas F M Porta is an academic researcher from Northwestern University. The author has contributed to research in topics: Bronchopulmonary dysplasia & Congenital diaphragmatic hernia. The author has an hindex of 18, co-authored 40 publications receiving 1164 citations. Previous affiliations of Nicolas F M Porta include University of California, San Francisco & Children's Memorial Hospital.

Papers
More filters
Journal ArticleDOI

Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia

TL;DR: BW-for-GA is an important predictor of PHTN in premature infants with moderate–severe BPD, and contributes to the growing evidence supporting fetal mechanisms of later onset pulmonary vascular disease.
Journal ArticleDOI

Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide.

TL;DR: Oxygenation rapidly improved after inhalation of PGI(2) in all infants, and one infant subsequently deteriorated, and alveolar capillary dysplasia was found at autopsy.
Journal ArticleDOI

Differential Patterns of 27 Cord Blood Immune Biomarkers Across Gestational Age

TL;DR: The distribution of immune biomarkers in cord blood across gestational age is described and the association between biomarker level patterns and preterm birth is investigated to provide important information that could be used to guide additional studies aimed at determining mechanisms that contribute to pre term birth.
Journal ArticleDOI

Placental pathologic changes of maternal vascular underperfusion in bronchopulmonary dysplasia and pulmonary hypertension

TL;DR: Placental MVU may identify BPD infants who were exposed to intrauterine hypoxia-ischemia, which increases their risk for development of PH disease, and further increased with PH.
Journal ArticleDOI

Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.

TL;DR: Currently available therapies for pulmonary hypertension, their biologic rationales, and evidence for their clinical effectiveness are discussed.